|
|
|
|
|
19.08.25 - 14:06
|
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors (Business Wire)
|
|
|
New board members bring decades of experience in company building, corporate strategy, drug development, and commercialization across multiple therapeutic areasCAMBRIDGE, Mass.--(BUSINESS WIRE)--#engineering--eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the appointment of Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors.
Douglas Williams, Ph.D., brings more than 30 years of leadership experience in the biopharmaceutical industry, including senior executive roles at Biogen, ZymoGenetics, Amgen, and Seattle Genetics (now Seagen). He has contributed to the development of several blockbuster therapies, including Enbrel®, Tecfidera® and Spinraza®. Most recently, he served as President of R&D at Sana Biotechnology and as founding CEO of Codiak Biosciences. Dr. Williams currently serves on the boards of Climb Bio (Chair) and CAMP4 Therapeutics.
Adam Craig, M.D., Ph.D., is a biotechnology exe...
|
|
|
14.08.25 - 16:18
|
Biogen Aktie: Wettbewerb kein Nullsummenspiel - Kursziel 118 USD (Aktiencheck)
|
|
|
Minneapolis (www.aktiencheck.de) - Biogen-Aktienanalyse von Piper Sandler:
Die Analysten von Piper Sandler haben das Kursziel für die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) von 115 USD auf 118 USD angehoben und das Rating "neutral" bestätigt. [mehr]...
|
|
|
12.08.25 - 18:06
|
Biogen Sees Potential in Combining Alzheimer′s and Obesity Drugs (Bloomberg)
|
|
|
If Novo Nordisk A/S's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer's disease, Biogen Inc.'s Chief Executive Officer Chris Viehbacher doesn't see it as a roadblock for his company's medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy....
|
|
|
|
|
06.08.25 - 13:30
|
Japan OKs Price Cut for Alzheimer′s Drug Lecanemab (Nippon)
|
|
|
Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and U.S. industry peer Biogen Inc., by 15 pct in Japan starting Nov. 1. The decision is based on an assessment by the Central Social Insurance Medical Council that cited the low cost-effectiveness of the drug us......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.25 - 22:06
|
Sage Therapeutics Announces Second Quarter 2025 Financial Results (Business Wire)
|
|
|
Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter
Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025
Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025.
“Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “As we work with Supernus to complete the transaction, we take pride in the progress made to date and remain focused on the important work of he...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
